Advancing our understanding of the mechanisms regulating human immune response
The NIH Cooperative Centers on Human Immunology (CCHI) were awarded in response to RFA-AI-22-069 to support research on human immune system regulation and function for the discovery and characterization of new principles of human immunology for the prevention and treatment of infectious and immune-mediated diseases. The CCHI U19 program supports mechanistic and hypothesis-testing studies to discover novel molecules, mechanisms, or regulatory pathways governing function of the human immune system in both healthy and vulnerable populations (i.e., across lifespan, organ/tissue transplant recipients, pregnant women). Studies of interest include immunity related to prevention or treatment of infectious diseases, immune-mediated pathogenesis/sequelae associated with infectious disease, and/or immune-mediated diseases. The overarching goal of the CCHI is to provide foundational information on human immune system function to support translation of immunology research into clinical benefits.
This current cycle represents the 5th cycle of funding for the U19 human immunology funding mechanism. Several of our current CCHI center members are repeat awardees. Emory University and Stanford University have begun their 5th cycle of funding (since 2003); Massachusetts General Hospital is on its 4th cycle (since 2009); and Jackson Laboratory, La Jolla Institute for Immunology, and the University of Alabama at Birmingham, which is also hosting the Infrastructure and Opportunity Fund Management Core, are beginning their 2nd cycle of funding (since 2019) via the CCHI mechanism. Returning to the CCHI cohort is the University of Maryland, Baltimore (funded in the 2nd and 3rd cycles), and new to the group are Northwestern University at Chicago and Washington University. See the Members for information on current sites and funded components.
